Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M198,877Revenue (TTM) $M41,729Net Margin (%)8.0Altman Z-Score3.9
Enterprise Value $M212,418EPS (TTM) $1.3Operating Margin %20.7Piotroski F-Score8
P/E(ttm)61.2Beneish M-Score-3.0Pre-tax Margin (%)19.1Higher ROA y-yY
Price/Book6.310-y EBITDA Growth Rate %-0.2Quick Ratio1.2Cash flow > EarningsY
Price/Sales5.05-y EBITDA Growth Rate %-5.9Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow23.1y-y EBITDA Growth Rate %55.7ROA % (ttm)3.8Higher Current Ratio y-yY
Dividend Yield %2.6PEG--ROE % (ttm)9.8Less Shares Outstanding y-yY
Payout Ratio %154Shares Outstanding M2,600ROIC % (ttm)7.3Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

MRK is held by these investors:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History

MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PERLMUTTER ROGER MExe V-P & Pres, MRL 2018-11-08Sell225,443$75.271.61view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2018-11-07Sell36,218$75.141.78view
Schechter Adam HEVP & Pres-Global Human Health 2018-11-01Sell277,879$73.813.62view
Watson AshleySVP Chief Ethics & Com Officer 2018-10-31Sell47,036$74.332.89view
DeLuca Richard R.EVP&Pres, Merck Animal Health 2018-10-30Sell25,467$726.22view
FRAZIER KENNETH CChairman, President & CEO 2018-10-02Sell279,850$72.076.12view
FRAZIER KENNETH CChairman, President & CEO 2018-09-18Sell279,851$70.089.13view
Schechter Adam HEVP & Pres-Global Human Health 2018-09-17Sell107,360$70.188.98view
Chattopadhyay SanatExe V-P & Pres. MMD 2018-08-03Sell29,208$65.217.3view
Karachun Rita ASr. VP Fince-Global Controller 2018-08-02Sell5,000$65.0117.64view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

News about MRK:

Articles On GuruFocus.com
BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy an Dec 06 2018 
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combina Nov 20 2018 
BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Stud Nov 19 2018 
Daniel Loeb Purchases 7 Stocks in 3rd Quarter Nov 13 2018 
5 Companies Hit 52-Week Highs Nov 06 2018 
Merck Publishes Corporate Responsibility Report Sep 20 2018 
The FDA Approves Merck's Anti-HIV-1 Drugs Aug 31 2018 
5 Companies Hit 52-Week Highs Aug 21 2018 
US Market Indexes Continue Gains on Monday Aug 20 2018 
Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patien Aug 17 2018 

More From Our Partners
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Dec 14 2018 - ZACKS
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat